{"id":14070,"date":"2019-09-19T09:08:40","date_gmt":"2019-09-19T13:08:40","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14070"},"modified":"2019-09-19T09:08:40","modified_gmt":"2019-09-19T13:08:40","slug":"why-didnt-nonprofits-and-the-nih-require-reasonable-pricing-for-zolgensma-that-may-happen-in-france","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14070","title":{"rendered":"Why didn\u2019t nonprofits and the NIH require \u2018reasonable\u2019 pricing for Zolgensma? That may happen in France"},"content":{"rendered":"<p>(By James Love for ST<em>A<\/em>T)<\/p>\n<p>When a new drug emerges from research largely funded by grants from charities and government agencies, who gets to set the price? In the U.S., that question seems to have been answered \u2014 the drug company that makes it. As I\u2019ve learned from a poorly redacted filing with the Securities and Exchange Commission, the answer may be different in France.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2019\/09\/18\/zolgensma-reasonable-pricing-france\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By James Love for STAT) When a new drug emerges from research largely funded by grants from charities and government<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,21,20,15,39],"tags":[],"class_list":["post-14070","post","type-post","status-publish","format-standard","hentry","category-emerging-health-issues","category-health-care-finance","category-health-care-redesign","category-part-dprescription-drugs","category-price-transparency"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14070"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14070\/revisions"}],"predecessor-version":[{"id":14071,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14070\/revisions\/14071"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}